Perrigo (NYSE:PRGO) Shares Down 4.8% – What’s Next?

Perrigo Company plc (NYSE:PRGO)’s stock price traded down 4.8% on Thursday . The stock traded as low as $10.75 and last traded at $10.63. 839,344 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 3,015,777 shares. The stock had previously closed at $11.17.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group cut their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings cut shares of Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.33.

Perrigo Stock Down 3.1%

The business’s 50 day moving average price is $11.18 and its 200 day moving average price is $12.47. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -0.82, a PEG ratio of 1.33 and a beta of 0.51. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The firm had revenue of $841.80 million for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the company earned $0.60 EPS. The firm’s revenue for the quarter was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, equities analysts forecast that Perrigo Company plc will post 2.11 EPS for the current year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 16th. Investors of record on Friday, May 29th will be paid a $0.29 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a yield of 10.7%. Perrigo’s dividend payout ratio (DPR) is currently -8.85%.

Institutional Investors Weigh In On Perrigo

A number of institutional investors have recently added to or reduced their stakes in PRGO. Amundi grew its stake in Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after acquiring an additional 556 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Perrigo by 126.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after purchasing an additional 647,982 shares in the last quarter. United Services Automobile Association purchased a new position in Perrigo in the 1st quarter valued at $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Perrigo by 6.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after purchasing an additional 32,151 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares in the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.